Zhou Y, Gottesman M M, Pastan I
Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Arch Biochem Biophys. 1999 Jul 1;367(1):74-80. doi: 10.1006/abbi.1999.1221.
P-glycoprotein (P-gp), encoded by the MDR1 gene, is a plasma membrane transporter which confers resistance to many chemotherapeutic drugs. Monoclonal antibodies raised against P-gp have been used as tools to study P-gp topology and activity. Monoclonal antibody UIC2 recognizes a functional conformation of P-gp on the cell surface and blocks P-gp-mediated drug transport. Knowledge about the UIC2 epitope and the mechanism of its inhibitory effects may be helpful for understanding P-gp structure and developing P-gp inhibitors. In the present work, using several chimeras of MDR1 and MDR2, we found that the native sequence of the predicted extracellular loop between transmembrane domains (TM) 5 and 6 of P-gp is necessary, but not sufficient, for UIC2 reactivity. In addition, UIC2 reactivity is also affected by mutations in TM6, a region known to be involved in interactions of P-gp with substrates. These observations suggest that residues in the extracellular loop between TM5 and TM6 are directly involved in the display of the UIC2 epitope. Since TM6 has been shown to be actively involved in drug transport process, the proximity of this region to TM6 may help to explain why UIC2 binding is sensitive to the functional state of P-gp and why binding of UIC2 inhibits P-gp-mediated drug transport.
由多药耐药基因1(MDR1)编码的P-糖蛋白(P-gp)是一种质膜转运蛋白,可赋予细胞对多种化疗药物的抗性。针对P-gp产生的单克隆抗体已被用作研究P-gp拓扑结构和活性的工具。单克隆抗体UIC2可识别细胞表面P-gp的一种功能构象,并阻断P-gp介导的药物转运。了解UIC2表位及其抑制作用机制可能有助于理解P-gp的结构并开发P-gp抑制剂。在本研究中,我们使用了几种MDR1和MDR2的嵌合体,发现P-gp跨膜结构域(TM)5和6之间预测的细胞外环的天然序列对于UIC2反应性是必要的,但不是充分的。此外,UIC2反应性还受TM6中突变的影响,TM6是已知参与P-gp与底物相互作用的区域。这些观察结果表明,TM5和TM6之间细胞外环中的残基直接参与UIC2表位的呈现。由于TM6已被证明积极参与药物转运过程,该区域与TM6的接近性可能有助于解释为什么UIC2结合对P-gp的功能状态敏感,以及为什么UIC2的结合会抑制P-gp介导的药物转运。